News | December 16, 2014

Findings indicate that stronger signal is obtained when 3-D thresholded SPECT scan is performed rather than conventional SPECT scan; similar results may be obtained for other psychiatric disorders

Nuclear imaging, Clinical trial/study, ADHA, 3-D SPECT imaging

December 16, 2014 — A recently published study from Toronto, Canada found that patients who utilized 3-D SPECT were able to get a clearer diagnosis of ADHD, which is the most common psychiatric disorder in children and adults.

Published in the Journal of Neuropsychiatry and Clinical Neurosciences, the study used 3-D SPECT imaging, a nuclear medicine study that evaluates blood flow and activity levels in the brain. This research demonstrated that 3-D SPECT imaging is a beneficial tool for ruling in or out ADHD.

This study is important because of the way the SPECT scans were rendered. The 3-D renderings made the scans easier to read than the typical 2-D images, which required greater reading skills of the physicians. In the present study, 3-D thresholded SPECT scans gave a sensitivity of 83% in predicting which patients would have a clinical diagnosis of ADHD compared with a sensitivity of 10% for the conventional 2-D SPECT scans. A 10% sensitivity hardly makes SPECT scans useful for clinical psychiatric applications, which is why some researchers have criticized the use of traditional SPECT.

Daniel G. Amen, M.D., psychiatrist and founder of Amen Clinics, who is referenced in the published article but did not participate in this particular study, says, "This study points to a significant advancement in the care of people who suffer with ADHD and other psychiatric disorders. Until now, standard diagnoses in psychiatry are made primarily through talking to patients and looking at symptom clusters without any biological information. Psychiatry is the only medical specialty that virtually never looks at the organ it treats.”

For more information: www.neuro.psychiatryonline.org/doi/abs/10.1176/appi.neuropsych.12110280

 

Related Content

News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
Subscribe Now